【摘要】 目的探讨血清中可溶性CD154(sCD154)、可溶性NF-KL激活受体(sRANKL)、骨保护素(OPG)水平与郎格罕细胞组织细胞增生症(LCH)发病机制关系。方法应用ELISA方法分别检测12例LCH患者(包括5例单系统多部位患者和7例多系统多部位患者)初诊及在治疗6周后血清sCD154、sRANKL和OPG水平,并对研究结果进行统计学分析。结果12例LCH患儿组与对照组比较,sCD154、sRANKL和OPG显著增高,而sRANKL/OPG比率明显降低。MM型组与SM型组相比较,血清sCD154、sRANKL、OPG水平以及sRANKL/OPG比率均无明显变化,但是OPG水平以及sRANKL/OPG比率与骨损害的数目相关。治疗前后比较,sCD154、sRANKL、OPG水平在治疗后有明显下降。结论血清sCD154、sRANKL、OPG可能与LCH的发病有关,而血清sRANKL/OPG比率是LCH患者发生溶骨性损害的标志。更多还原

【Abstract】 Objective To investigate relationship between CD154 (sCD154),receptor activator of NF-kB ligand (sRANKL),osteoprotegerin (OPG) and Langerhans cell histiocytosis (LCH) pathogenesis. Methods Blood samples were obtained from the 12 patients (single-system multi-site (SM type),and multi-system multi-site (MM type))before and after the 6-week induction therapy,respectively,sCD154,sRANKL,and OPG in each sample were measured in duplicate by the ELISA according to the manufacturer’s instructions. Results were producted from statistic analysis. Results The values of sCD154,sRANKL,and OPG in sera were remarkably higher in patients with LCH compared with contrast group,while the sRANKL/OPG ratio were significantly lower in patients with LCH compared with controls. Serum levels of sCD154,sRANKL,and OPG,and the sRANKL/OPG ratio were not significantly elevated in the MM type compared with the SM type. OPG and the sRANKL/OPG ratio were positively correlated with the number of bone lesions. In patients who responded to the induction therapy,serum levels of sRANKL,and OPG,and the sRANKL decreased significantly after the therapy. Conclusions We can forecast sCD154,sRANKL and OPG are probably biochemical markers relates to LCH pathogenesis,and sRANKL/OPG ratios is a marker of osteolytic activity in LCH patients.更多还原